1 |
Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-648.
DOI
|
2 |
Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987;5:313-341.
DOI
|
3 |
Chapman JD, Urtasun RC, Blakely EA, Smith KC, Tobias CA. Hypoxic cell sensitizers and heavy charged-particle radiations. Br J Cancer Suppl 1978;37:184-188.
|
4 |
Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265-280.
DOI
|
5 |
Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med 2001;31:321-329.
DOI
|
6 |
Webster LT. Drugs used in chemotherapy of protozal infections. In: Gilman AG, Rall TW, Nies AS, Taylor P. eds. The pharmacological basis of therapeutics. 8th edn. New York. Perganon 1990:1002-4
|
7 |
Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, Krohn KA, Griffin TW. Imaging of hypoxia in human tumors with [F-18] fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199-212.
DOI
|
8 |
Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133-2137.
|
9 |
Rasey JS, Hofstrand PD, Chin LK, Tewson TJ. Characterization of [ ]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999;40:1072-1079.
|
10 |
Yeh SH, Liu RS, Wu LC, Yang DJ, Yen SH, Chang CW, Yu TW, Chou KL, Chen KY. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996;23:1378-1383.
DOI
|
11 |
Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, Podoloff DA. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995;194:795-800.
DOI
|
12 |
Gronroos T, Eskola O, Lehtio K, Minn H, Marjamaki P, Bergman J, Haaparanta M, Forsback S, Solin O. Pharmacokinetics of [ ]FETNIM: a potential marker for PET. J Nucl Med 2001;42:1397-1404.
|
13 |
Dolbier WR Jr, Li AR, Koch CJ, Shiue CY, Kachur AV. [ ]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 2001;54:73-80.
DOI
|
14 |
Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, Wester HJ, Beck R, McEwan AJ, Wiebe LI, Schwaiger M. Hypoxia-specific tumor imaging with -fluoroazomycin arabinoside. J Nucl Med 2005;46:106-113.
|
15 |
Zanzonico P, O'Donoghue J, Chapman JD, Schneider R, Cai S, Larson S, Wen B, Chen Y, Finn R, Ruan S, Gerweck L, Humm J, Ling C. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004;31:117-128.
DOI
|
16 |
Das T, Banerjee S, Samuel G, Sarma HD, Korde A, Venkatesh M, Pillai MR. -labeling studies of a modified metronidazole and its biodistribution in tumor bearing animal models. Nucl Med Biol 2003;30:127-134.
DOI
|
17 |
Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI. Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med 1991;32:1764-1770.
|
18 |
Ballinger JR, Kee JW, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 1996;37:1023-1031.
|
19 |
Johnson LL, Schofield L, Mastrofrancesco P, Donahay T, Nott L. Technetium-99m-nitroimadazole uptake in a swine model of demand ischemia. J Nucl Med 1998;39:1468-1475.
|
20 |
Melo T, Duncan J, Ballinger JR, Rauth AM. BRU59-21, a second-generation -labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med 2000;41:169-176.
|
21 |
Hoigebazar L, Jeong JM, Choi SY, Choi JY, Shetty D, Lee YS, Lee DS, Chung JK, Lee MC, Chung YK. Synthesis and characterization of nitroimidazole derivatives for -labeling and testing in tumor xenografted mice. J Med Chem 2010;53:6378-6385.
DOI
|
22 |
Fritzberg AR, Kasina S, Eshima D, Johnson DL. Synthesis and biological evaluation of technetium-99m as a hippuran replacement. J Nucl Med 1986;27:111-116.
|
23 |
Itoh K. - : review of pharmacokinetics, clinical application to renal diseases and quantification of renal function. Ann Nucl Med 2001;15:179-190.
DOI
|
24 |
Eshima D, Fritzberg AR, Taylor A Jr. renal tubular function agents: current status. Semin Nucl Med 1990;20:28-40.
DOI
|
25 |
Linder KE, Chan YW, Cyr JE, Malley MF, Nowotnik DP, Nunn AD. TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction. J Med Chem 1994;37:9-17
DOI
|
26 |
Eshima D, Taylor A Jr. Technetium-99m ( ) mercaptoacetyltriglycine: update on the new renal tubular function agent. Semin Nucl Med 1992;22:61-73.
DOI
|